STAT

Opinion: I’ve been forced to go through ‘step therapy.’ Don’t make Medicare Part B participants do that

Insurers' overzealous use of step therapy is designed to bolster their bottom lines at the expense of people the people they're meant to serve.

For roughly half my life, I have suffered from debilitating joint pain and inflammation that left me drained, fatigued, and, eventually, struggling to walk. At first, no one knew what was wrong with me. Then I was misdiagnosed. Finally, just as I started my sophomore year in college, my doctors told me I had a severe case of rheumatoid arthritis (RA), an incurable, progressive, and ultimately crippling illness. I was forced to drop out of school for a while. For a long time I could not work full time.

That happened more than 15 years ago. Now, after three surgeries and countless medications, I am able to live what resembles a normal life. But

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks